Browse diseases

…ld be a potential predictor of immune-related adverse events in renal cell carcinoma. J Pers Med. 2022 May;12(6):888.Ramos-Casals M, Brahmer JR, Cal…

…Background Melanoma brain metastases (MBM) affect approximately 60% of patients with metastatic mela…

…tial success in hematologic cancers. However, their efficacy in solid tumors remains limited, largely due to T-cell exhaustion (TEX), a dysf…

…us success of chimeric antigen receptor (CAR) T cell therapy in haematological malignancies has not been recapitulated in the solid tumour setting, owing t…

…mor-infiltrating lymphocyte (TIL) therapy recently approved for advanced/metastatic melanoma – and up to six interleukin-2 (IL-2) doses, 1 2 ‘rash’ was a tr…

…a key mediator of clinical responses in metastatic melanoma and gastrointestinal cancers. 1 2 However, the baseline molecular features defining neoantig…

…To uncover immune correlates of response to moDC vaccination in metastatic melanoma, we conducted a comprehensive multi-omics analysis of the initi…

…ociated with a near doubling of OS among patients with Stage IV NSCLC (555 days vs 1120 days, adj HR 0.5, 95% CI 0.4-0.7) and Stage I…

…nes) patients with immune checkpoint inhibitor (ICI)-refractory MM (8 cutaneous, 5 mucosal, 4 uveal) received TILT-123 intravenous…

…Background Unleashing the immune anti-tumor response against metastatic melanoma through immune checkpoint blockade (ICB) therapies have redefin…

…Background Metastatic melanoma is the leading cause of skin cancer-related deaths, with a five…

… induced liver injury (ChILI) post nivolumab and ipilimumab for metastatic melanoma. Despite treatment with immunosuppression, the liver enzymes im…